![PCE artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts124/v4/94/32/1a/94321aaa-4adf-3df2-4810-f996719b6b1e/mza_11695467358112480520.jpg/100x100bb.jpg)
HCC: Treatment-Related Adverse Events, Case Discussions and Q&A – Episode 2
PCE
English - February 25, 2022 14:00 - 31 minutes - 28.6 MB - ★★★★ - 6 ratingsCourses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this second episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss how to identify, prevent and mitigate treatment-related adverse events, and review cases with careful considerations for patient-specific factors guiding treatment selection, followed by a question-and-answer session on the management of patients with HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Amit Singal, MD, MS
Mark Yarchoan, MD
Bridget O’Brien, DNP, FNP-BC, AOCNP
Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.
Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.
Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.